To evaluate ocular hypertension (OHT) after Ozurdex injection to determine the incidence of OHT, therapy for OHT, and any associative factors such as diagnosis, underlying glaucoma and therapy, or sequential Ozurdex injection(s).
Retrospective consecutive case series with patients receiving one or more intravitreal Ozurdex implantations at a tertiary care academic center. Ocular hypertension was defined as a single measurement of ≥30 mmHg or an increase of ≥10 mmHg from baseline.
Ninety-four injections in 52 patients (59 eyes) were reviewed. Forty eyes received a single injection, and 19 eyes received multiple injections. Ocular hypertension developed in 14 patients (26.9%). Thirteen patients (25%) had preexisting glaucoma or suspicion of glaucoma, and 6 of these developed OHT. Glaucoma eye drops were initiated after 13 injections (13.8%). Invasive surgery for glaucoma was required in 3 patients (3.2%): all had glaucoma or suspicion of glaucoma (one case was related to neovascular glaucoma and unlikely related to steroid response after Ozurdex). There was no difference in relative intraocular pressure increase (i.e., difference between final follow-up or subsequent intravitreal injection vs. baseline) between single versus multiple Ozurdex injections (P = 0.883).
Patients (26.9%) who received Ozurdex developed OHT. Glaucoma or glaucoma-suspicion factors were present in all patients who required invasive surgery for glaucoma. A greater proportion of patients who received multiple injections had an intraocular pressure elevation, but the relative intraocular pressure increase was not significant.
Patients (26.9%) who received single or multiple Ozurdex injections developed ocular hypertension. Glaucoma or glaucoma-suspicion factors were present in all patients who required invasive surgery for glaucoma. A greater proportion of patients who received multiple injections had an intraocular pressure elevation, but the relative intraocular pressure increase was not significant.
*Department of Ophthalmology and Visual Sciences, Vitreoretinal Service, Omics Laboratory, University of Iowa, Iowa City, Iowa;
†Retina Consultants of Southern California, Redlands, California;
‡VitreoRetinal Surgery PA, Minneapolis, Minnesota; and
§Department of Ophthalmology, Queen's University, Kingston, Ontario, Canada.
Reprint requests: Vinit B. Mahajan, MD, PhD, The University of Iowa, Carver College of Medicine, 200 Hawkins Drive, Iowa City, IA 52242; e-mail: email@example.com
Supported by an unrestricted grant from the Research to Prevent Blindness. V.B.M. is supported by NIH Grant K08EY020530.
G. Velez is supported by T32GM007337. None of the authors has a conflict of interest to disclose.